Takeda logo

Understanding ALK+ NSCLC: Causes, Prevalence, and Prognosis | Takeda Oncology

Disease Education

Outsmarting Cancer to Profoundly Impact Patients’ Lives

image alt text

At Takeda Oncology, we aspire to cure cancer with inspiration from patients and innovation from everywhere. We combine rigorous science, innovative commercial operations and the aspiration of transforming cancer from a serious disease to a treatable illness in our efforts to develop transformative medicines. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.

Cancer is clever, but we know its weaknesses. We’ve discovered new ways to attack vulnerabilities in cancer that affect specific patient populations with significant unmet need.

Patients with limited or ineffective treatment options motivate us every day. We are committed to outsmarting cancer so that more patients can benefit from – and have access to – life-transforming medicines.


Colorectal Cancer

Colorectal cancer (CRC) is cancer of the large intestine, which is made up of the colon and rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start.1 CRC is the third most common cancer worldwide. In 2020, CRC represented about 1 in 10 cancer cases and deaths.2 By 2030, CRC is expected increase by 60%, to over 2.2 million new cases and 1.1 million deaths globally.3

Metastatic Colorectal Cancer

Metastatic Colorectal cancer can also be referred to as advanced colon cancer or stage 4 colon cancer.4


Lung Cancer

Lung cancer is one of the most common cancers and is the leading cause of cancer death worldwide. Even with substantial improvement in cancer screening, diagnosis, and treatment over the past few decades, lung cancer remains the leading cause of cancer death, with approximately 18% of cancer-related deaths worldwide. 1 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all forms of lung cancer.

Takeda Oncology’s advanced lung cancer research is focused on expanding treatment options for people with anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC (mNSCLC). Our ongoing investigation of targeted therapies demonstrates continued progress toward extending and improving the lives of people living with rare forms of NSCLC.

image alt text

Anaplastic lymphoma kinase-positive (ALK+) NSCLC is a unique type of NSCLC caused by a change in the anaplastic lymphoma kinase (ALK) gene.


Blood Cancer

Hematologic malignancies, or blood cancers, include leukemia, lymphoma, myeloma and myelodysplastic syndromes (MDS). These types of blood cancers can affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system. Each year, more than 1.3 million people worldwide are diagnosed with a blood cancer.

Lymphoma

Lymphoma is the most common type of blood cancer and originates from abnormal lymphocytes, a key component of the human immune system. 3

Multiple Myeloma

Multiple myeloma is a rare blood cancer that arises from the plasma cells, a type of white blood cell which is made in the bone marrow.

Leukemia

Leukemia is a blood cancer that develops in early blood-forming cells. There are four main types of Leukemia.

1 WHO Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=lung. Accessed January 26, 2018.  2 American Cancer Society. What is Lung Cancer? https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed July 29, 2020. 3  Lymphoma Research Foundation. About Lymphoma. https://lymphoma.org/aboutlymphoma/. Accessed January 2021. 4  Memorial Sloan Kettering Cancer Center. Treatment for Metastatic Colon Cancer. Available at: https://www.mskcc.org/cancer-care/types/colon/treatment/metastases

Explore More

Card image

Oncology Pipeline

Discovering and developing innovative therapies to deliver potentially transformative treatments.
Card image

R&D Approach

Decades of leadership in Oncology with a diverse and robust pipeline.
patient advocacy

Patient Advocacy

We are committed to helping people with cancer navigate every part of their journey.

All trademarks are the property of their respective owners.

©2024 Takeda Pharmaceuticals U.S.A., Inc.

All rights reserved.   01/23